Antibody Engineering and Therapeutics
Juan C. Almagro(Pfizer (United States)), Kai Xu(Memorial Sloan Kettering Cancer Center), Matthias Pauthner(Scripps Research Institute), Fridtjof Lund‐Johansen(Oslo University Hospital), Stefan Barghorn(Ludwigshafen University of Business and Society), Gustavo Helguera(Centro Científico Tecnológico - Tucumán), Paul W.H.I. Parren(Leiden University Medical Center), Jamie K. Scott(Simon Fraser University), James E. Crowe(Vanderbilt University Medical Center), Devin Sok(Scripps Research Institute), Raiees Andrabi(Scripps Research Institute), James S. Huston(University of Maine), James E. Voss(Scripps Research Institute), Eric Krauland(Adimab (United States)), Gary L. Gilliland(National Institute of Standards and Technology), Mathieu Bléry(Innate Pharma (France)), Lubna Abuqayyas(Amgen (United States)), Robert L. Mabry(Dartmouth College), Felix Breden(Simon Fraser University), Juha Laurén(Regeneron (United States)), Stephen Albert Johnston(Phoenix (United States)), Wayne A. Marasco(Dana-Farber Cancer Institute), Eshel Ben‐Jacob(Tel Aviv University), Janice M. Reichert(Framingham State University)
Cited by 6
Related Papers
The Protein Data Bank
|Acta Crystallographica Section D Biological Crystallography|2002|2.6k
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
|Cell Host & Microbe|2020|1.2k
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
|The Journal of Immunology|2010|1k